These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 23067526

  • 1. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
    Ochoa-Figueroa MA, Uña-Gorospe J, Allende-Riera A, Cárdenas-Negro JC, Muñoz-Iglesias J, Cabello-García D, De Sequera-Rahola M, Martínez-Gimeno E.
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
    [Abstract] [Full Text] [Related]

  • 2. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, Has D, Isik G, Asoglu O, Kapran Y, Adalet I.
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [Abstract] [Full Text] [Related]

  • 3. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E, Soydal C, Araz M, Aras G.
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH.
    Hepatogastroenterology; 2006 Sep; 53(69):348-50. PubMed ID: 16795969
    [Abstract] [Full Text] [Related]

  • 5. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E, Soydal C, Araz M, Kir KM, Ibis E.
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of efficacy and clinical impact of FDG-PET in patients with suspicion of recurrent colorectal cancer].
    Borrego Dorado I, Gómez Camarero P, Ruiz Franco-Baux J, Vázquez Albertino R.
    Rev Esp Med Nucl; 2004 Apr; 23(5):313-23. PubMed ID: 15450136
    [Abstract] [Full Text] [Related]

  • 7. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E, Datseris IE, Rondogianni P, Vlontzou E, Skilakaki M, Exarhos D, Bamias A.
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [Abstract] [Full Text] [Related]

  • 8. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY, Kochhar R, Renehan AG, Manoharan P.
    ANZ J Surg; 2012 Oct; 82(10):729-36. PubMed ID: 22989147
    [Abstract] [Full Text] [Related]

  • 9. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U, You J, McSweeney S, Freeman M, Hendler A.
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z, Szefer J, Zuchora Z, Romanowicz G, Pietrzak T.
    Pol Merkur Lekarski; 2004 Mar; 17 Suppl 1():63-6. PubMed ID: 15603351
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M, Kubik M, Fisker RV, Thorlacius-Ussing O, Petersen LJ.
    Cancer Imaging; 2015 Aug 13; 15(1):11. PubMed ID: 26263901
    [Abstract] [Full Text] [Related]

  • 12. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
    Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, Paredes P, Lomeña F, Pons F.
    Rev Esp Med Nucl Imagen Mol; 2012 Aug 13; 31(3):111-6. PubMed ID: 22154291
    [Abstract] [Full Text] [Related]

  • 13. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
    Kyoto Y, Momose M, Kondo C, Itabashi M, Kameoka S, Kusakabe K.
    Ann Nucl Med; 2010 Jun 13; 24(5):395-401. PubMed ID: 20364373
    [Abstract] [Full Text] [Related]

  • 14. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH.
    Nucl Med Commun; 2010 Jun 13; 31(6):576-82. PubMed ID: 20216474
    [Abstract] [Full Text] [Related]

  • 15. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH.
    Anticancer Res; 2001 Jun 13; 21(2B):1375-8. PubMed ID: 11396217
    [Abstract] [Full Text] [Related]

  • 16. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S, Stojiljkovic M, Sobic-Saranovic D, Pandurevic S, Brajkovic L, Milosevic I, Grozdic-Milojevic I, Artiko V.
    Neoplasma; 2017 Jun 13; 64(6):954-961. PubMed ID: 28895416
    [Abstract] [Full Text] [Related]

  • 17. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
    Granados Rangel O, Estrada G, Altamirano J.
    Gac Med Mex; 2014 Jun 13; 150(6):509-17. PubMed ID: 25375281
    [Abstract] [Full Text] [Related]

  • 18. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M, Yener C, Karabulut E.
    Int J Comput Assist Radiol Surg; 2015 Jul 13; 10(7):993-1002. PubMed ID: 25213271
    [Abstract] [Full Text] [Related]

  • 19. Value of ¹⁸F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations.
    Zhang Y, Feng B, Zhang GL, Hu M, Fu Z, Zhao F, Zhang XL, Kong L, Yu JM.
    World J Gastroenterol; 2014 Jun 07; 20(21):6608-14. PubMed ID: 24914384
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vázquez-Albertino RJ, Navarro-González E, Ruiz-Franco-Baux JV, Cuenca-Cuenca JI.
    Rev Esp Med Nucl Imagen Mol; 2012 Sep 07; 31(5):261-6. PubMed ID: 23067528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.